Ipsen's Strategic Transformation: A Comprehensive Case Study
David Loew took over as CEO of Ipsen during a turbulent period marked by a 70% drop in share price due to the FDA’s hold on palovarotene, a drug for a rare bone disease. Concurrently, their flagship product, Somatuline, faced new generic competition, and the company’s R&D pipeline was heavily skewed towards late-stage assets, posing significant challenges.
Read More